[Translation] A randomized, open-label, single-dose, two-formulation, two-cycle, two-sequence, double-crossover bioequivalence study of insulin aspart injection in Chinese healthy subjects
主要目的: 采用正葡萄糖钳夹技术,在健康男性受试者中比较吉林津升制药有限公司研制的门冬胰岛素注射液与诺和锐®单剂量皮下注射药代动力学的生物等效性; 次要目的: 评价门冬胰岛素注射液在健康受试者中的安全性。
[Translation] Primary objective: To compare the bioequivalence of the pharmacokinetics of single-dose subcutaneous injection of insulin aspart injection developed by Jilin Jinsheng Pharmaceutical Co., Ltd. and NovoRapid® in healthy male subjects using the euglycemic clamp technique; Secondary objective: To evaluate the safety of insulin aspart injection in healthy subjects.